EA200000845A1 - Ген, кодирующий новый маркер рака - Google Patents

Ген, кодирующий новый маркер рака

Info

Publication number
EA200000845A1
EA200000845A1 EA200000845A EA200000845A EA200000845A1 EA 200000845 A1 EA200000845 A1 EA 200000845A1 EA 200000845 A EA200000845 A EA 200000845A EA 200000845 A EA200000845 A EA 200000845A EA 200000845 A1 EA200000845 A1 EA 200000845A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lab
cancer
preventing
protein
mentioned
Prior art date
Application number
EA200000845A
Other languages
English (en)
Other versions
EA003735B1 (ru
Inventor
Джеймз А. Радосевич
Original Assignee
Джеймз А. Радосевич
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джеймз А. Радосевич filed Critical Джеймз А. Радосевич
Publication of EA200000845A1 publication Critical patent/EA200000845A1/ru
Publication of EA003735B1 publication Critical patent/EA003735B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Выделяют молекулу кДНК, кодирующую белок, обозначенный как Labyrinthin (Lab), и определяют ее нуклеотидную последовательность. Упомянутый белок либо пептиды, полученные из упомянутого белка, являются маркерами, пригодными для определения раковых опухолей новых классов. В диагностических пробах для определения упомянутых раковых опухолей используются антитела к Lab либо нуклеотидные зонды, которые гибридизуются с упомянутым lab геном либо его фрагментом. В вакцинах, пригодных для предупреждения рецидива раковых опухолей у субъекта с положительной реакцией на Lab (либо lab) либо для профилактики начального возникновения раковой опухоли, используются белки либо пептиды, полученные из Lab. Экспрессия Lab посредством иммуногенных проб используется для контролирования результатом лечения рака. При лечении используются антисмысловые молекулы против lab. Смысловые молекулы lab используются для восстановления утраченной функции lab в нормальных больных клетках, например в железистых клетках.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000845A 1998-03-17 1999-03-11 Ген, кодирующий новый маркер рака EA003735B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof
PCT/US1999/005365 WO1999047683A1 (en) 1998-03-17 1999-03-11 Gene encoding labyrinthin, a marker for cancer

Publications (2)

Publication Number Publication Date
EA200000845A1 true EA200000845A1 (ru) 2001-08-27
EA003735B1 EA003735B1 (ru) 2003-08-28

Family

ID=21911225

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000845A EA003735B1 (ru) 1998-03-17 1999-03-11 Ген, кодирующий новый маркер рака

Country Status (15)

Country Link
US (7) US6166176A (ru)
EP (1) EP1062346B1 (ru)
JP (2) JP2002512005A (ru)
CN (2) CN101260401A (ru)
AP (1) AP2000001917A0 (ru)
AT (1) ATE337400T1 (ru)
AU (2) AU762758B2 (ru)
BR (1) BR9908886A (ru)
CA (1) CA2323494A1 (ru)
DE (1) DE69932926T2 (ru)
EA (1) EA003735B1 (ru)
HK (1) HK1033151A1 (ru)
IL (1) IL138208A0 (ru)
OA (1) OA11487A (ru)
WO (1) WO1999047683A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
EP1512695B1 (en) * 2003-09-04 2008-11-19 Biomay AG Hypoallergenic polypeptides based on fish parvalbumin
WO2005049802A2 (en) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
AU2019397539A1 (en) * 2018-12-13 2021-07-15 Labyrx Immunologic Therapeutics (Usa) Limited Labyrinthin-based peptides for cancer immunotherapies and uses thereof
CN113993892A (zh) * 2019-01-08 2022-01-28 莱比锡免疫治疗(美国)有限公司 靶向迷路蛋白或其部分的构建体以及所述构建体的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) * 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
BR0313536A (pt) * 2002-07-31 2005-06-14 Monsanto Technology Llc Sequencias de ácido nucléico de diacilglicerol acetiltransferase e produtos associados
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US8507754B2 (en) * 2009-01-31 2013-08-13 University Of North Texas Engineering lipids in vegetative tissues of plants
CN103201379B (zh) * 2010-06-28 2015-08-19 联邦科学技术研究组织 生产脂质的方法

Also Published As

Publication number Publication date
AP2000001917A0 (en) 2000-09-30
US20050208508A1 (en) 2005-09-22
JP2009165492A (ja) 2009-07-30
US7635759B2 (en) 2009-12-22
CN1301302A (zh) 2001-06-27
US8163883B2 (en) 2012-04-24
US20110110963A1 (en) 2011-05-12
JP2002512005A (ja) 2002-04-23
EP1062346B1 (en) 2006-08-23
IL138208A0 (en) 2001-10-31
WO1999047683A1 (en) 1999-09-23
CN100372938C (zh) 2008-03-05
US20100112582A1 (en) 2010-05-06
AU762758B2 (en) 2003-07-03
US20100233711A1 (en) 2010-09-16
ATE337400T1 (de) 2006-09-15
US20080249284A1 (en) 2008-10-09
EA003735B1 (ru) 2003-08-28
AU2003204331B2 (en) 2008-02-07
BR9908886A (pt) 2000-11-21
AU2999699A (en) 1999-10-11
DE69932926D1 (de) 2006-10-05
US7329743B2 (en) 2008-02-12
US6166176A (en) 2000-12-26
DE69932926T2 (de) 2007-05-24
CA2323494A1 (en) 1999-09-23
WO1999047683A9 (en) 1999-11-18
CN101260401A (zh) 2008-09-10
US6727080B1 (en) 2004-04-27
OA11487A (en) 2004-05-04
HK1033151A1 (en) 2001-08-17
EP1062346A1 (en) 2000-12-27

Similar Documents

Publication Publication Date Title
Paucha et al. Large and small tumor antigens from simian virus 40 have identical amino termini mapping at 0.65 map units.
JP6672411B2 (ja) 癌療法を示すためのｓｒｍアッセイ
Yu et al. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications
Vercoutter-Edouart et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
Rauch et al. Allogenic antibody-mediated identification of head and neck cancer antigens
CO4870792A1 (es) Compuestos y conjunto de medios de diagnostico para detectar y vigilar la progresion de cancer de prostata
SE9500023D0 (sv) Method of detecting cancer
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
CA2954051A1 (en) Srm assays to chemotherapy targets
Wu et al. An approach to the proteomic analysis of a breast cancer cell line (SKBR‐3)
ES2327063T3 (es) Determinacion de srl-alcohol deshidrogenasa de cadena corta (dhrs4) como biomarcador para inflamaciones e infecciones.
CN109517898B (zh) 一种食管癌检测、诊断或者预后评价制剂，治疗食管癌的药物及rnd2基因的应用
JP2019058171A (ja) Ｐｄ−ｌ１に対するｓｒｍアッセイ
JP6441215B2 (ja) 肺組織像を細分類するためのｓｒｍ／ｍｒｍ分析
Li et al. Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells
DE69126038T2 (de) Diagnose von krebs-metastasen durch das mts-1 gen
WO1998010291A1 (en) Biochemical markers of the human endometrium
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
ES2673125T3 (es) Ensayo SRM/MRM para medir el nivel de la proteína receptor 2 de efrina tipo A
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
CN106255766B (zh) 针对雄激素受体(ar)蛋白质的srm/mrm测定
Dall'Era et al. HSP27 and HSP70 interact with CD10 in C4‐2 prostate cancer cells
Taniguchi et al. Differential expression of smooth muscle α-like actin between benign and malignant human pigment tissues

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ MD TJ RU